Robert Breedlove
Vermogen: 639 946 $ op 31-08-2026
Vermogen: 639 946 $ op 31-08-2026
Robert Breedlove is Chief Accounting Officer & Vice President-Finance at Phathom Pharmaceuticals, Inc. since 2025.
Former roles include Manager-Financial Reporting & Compliance at NeoGenomics, Inc. and Senior Manager at Van Den Boom & Associates LLC.
Education includes an undergraduate degree from the University of San Diego.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 14-07-2026 | 66.870 ( 0,08% ) | 639 946 $ | 31-08-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 06-10-2025 |
| Bedrijven | Functie | Einde |
|---|---|---|
| NEOGENOMICS, INC. | Compliance Officer | - |
Van Den Boom & Associates LLC
Van Den Boom & Associates LLC Miscellaneous Commercial ServicesCommercial Services Provides accounting, financial, payroll, benefit and human resource services | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
NeoGenomics, Inc.
NeoGenomics, Inc. Medical/Nursing ServicesHealth Services Provides genetic and molecular testing services | Health Services |
University of San Diego
University of San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Van Den Boom & Associates LLC
Van Den Boom & Associates LLC Miscellaneous Commercial ServicesCommercial Services Provides accounting, financial, payroll, benefit and human resource services | Commercial Services |
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel treatments for gastrointestinal diseases and disorders | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau